Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338191 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL4687 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL3119262 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8192290 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5835621 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5544656 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8532996 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL6374631 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL27504027 | 0.98 | GRM5 (0.48) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5196221 | 0.91 | GRM5 (0.57) | GRM5CA2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| WO-2008119734-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| EP-1077926-B1 | PROPYLISOPROPYL ACETAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2005-02-23 | — | — | EP | claimed |
| US-20030225161-A1 | GABA and L-glutamic acid analogs for antiseizure treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | claimed |
| US-20030212131-A1 | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them | BIALER MEIR (IL) | 2003-11-13 | — | — | US | claimed |
| US-6630602-B1 | Racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-10-07 | — | — | US | claimed |
| EP-0925292-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED CHROMANOL DERIVATIVES | PFIZER (US) | 2003-09-10 | — | — | EP | claimed |
| EP-1077926-A1 | PROPYLISOPROPYL ACETIC ACID AND PROPYLISOPROPYL ACETAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-02-28 | — | — | EP | claimed |
| EP-0966429-A1 | VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-12-29 | — | — | EP | claimed |
| WO-1999054282-A1 | PROPYLISOPROPYL ACETIC ACID AND PROPYLISOPROPYL ACETAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 1999-10-28 | — | — | WO | claimed |
| WO-1998030536-A1 | VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | claimed |
| US-5599973-A | REACTING ACID CHLORIDE WITH SUBSTITUTED 2-OXAZOLIDINONE AND BUTYLLITHIUM, THEN BENZYL ALPHA-BROMOACETATE, HYDROGEN PEROXIDE, LITHIUM OXIDE, SODIUM METABISULFITE, BORANE DIMETHYL SULFIDE, THEN TOSYLATION, AZIDE FORMATION, AMINATION | NORTHWESTERN UNIVERSITY (US) | 1997-02-04 | — | — | US | claimed |
| US-4847275-A | ENZYME INHIBITOR, LEUKOTRIENE ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-07-11 | — | — | US | claimed |
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4426714-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-4864017-A | Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert | THE UPJOHN COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| EP-0237202-A2 | Novel renin inhibiting peptides having a dihydroxyethylene isostere transition state insert | THE UPJOHN COMPANY (US) | 1987-09-16 | — | — | EP | disclosed |
| WO-1987005302-A1 | NOVEL RENIN-INHIBITING PEPTIDES HAVING A DIHYDROXYETHYLENE ISOSTERE TRANSITION STATE INSERT | THE UPJOHN COMPANY (US) | 1987-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225161-A1 | GABA and L-glutamic acid analogs for antiseizure treatment | GABRB1, GABRE, GABRB2 | GRM5 50/4885CA2 319/4885SLC6A2 1005/4885 |
| US-20030212131-A1 | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them | ADCYAP1R1, GRIN2A, PTGER1 | GRM5 118/4885CA2 1385/4885SLC6A2 2539/4885 |
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | FCGR2A, FCGR3B, AURKC | GRM5 1466/4885CA2 1552/4885SLC6A2 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.